The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | STAIR: time-limited acalabrutinib monotherapy in frail patients with previously untreated CLL
Romain Guieze, MD, PhD, CHU Clermont Ferrand, Clermont Ferrand, France, discusses results from the Phase II STAIR trial (NCT04963946) evaluating treatment discontinuation after 18 months of acalabrutinib in frail, older patients with previously untreated chronic lymphocytic leukemia (CLL). Although stopping therapy did not meet the primary progression-free survival (PFS) endpoint, some patients, particularly those with mutated immunoglobulin heavy chain gene (IgHV), maintained favorable outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
